Technical Analysis for UTHR - United Therapeutics Corporation
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bearish Signal Line Cross | Bearish | 0.00% | |
20 DMA Support | Bullish | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Down 5 Days in a Row | Weakness | 0.00% | |
Down 3 Days in a Row | Weakness | -0.77% | |
Down 4 Days in a Row | Weakness | -0.77% | |
Overbought Stochastic | Strength | -1.74% | |
Down 3 Days in a Row | Weakness | -1.74% | |
Slingshot Bullish | Bullish Swing Setup | -3.03% |
Alert | Time |
---|---|
20 DMA Support | about 19 hours ago |
Down 2 % | about 20 hours ago |
Fell Below 20 DMA | about 20 hours ago |
Down 1% | about 21 hours ago |
Fell Below Previous Day's Low | about 21 hours ago |
Get a Trading Assistant
- Earnings date: 05/01/2024
United Therapeutics Corporation Description
United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product is Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops oral treprostinil, an orally delivered prostacyclin analog for treatment of pulmonary hypertension; Ch14.18 MAb, an antibody in Phase III clinical trials for the treatment of neuroblastoma; Beraprost 314d, which is entering Phase III clinical trails for the treatment of PAH; PLacental eXpanded cells, which are entering a Phase I trial for the treatment of PAH; and 8H9 MAb, an antibody that is under Phase I clinical trial for the treatment of metastatic brain cancer. Further, the company is involved in the pre-clinical stage of developing TransCon Treprostinil, TransCon Beraprost, and glycobiological antiviral agents for the treatment of infectious diseases, such as Hepatitis C; and engineered lungs and lung tissue, which can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Infectious Diseases Alcohol Organic Compounds Chemical Compounds Hypertension Blastoma Pulmonary Arterial Hypertension Hepatitis C Pulmonary Hypertension Neuroblastoma Brain Cancer Lung Diseases Treprostinil Chronic And Life Threatening Conditions Oral Therapy Treatment Of Infectious Diseases
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 261.48 |
52 Week Low | 204.44 |
Average Volume | 391,420 |
200-Day Moving Average | 227.77 |
50-Day Moving Average | 223.27 |
20-Day Moving Average | 231.86 |
10-Day Moving Average | 239.53 |
Average True Range | 6.28 |
RSI (14) | 53.92 |
ADX | 43.72 |
+DI | 26.65 |
-DI | 20.04 |
Chandelier Exit (Long, 3 ATRs) | 231.52 |
Chandelier Exit (Short, 3 ATRs) | 230.45 |
Upper Bollinger Bands | 250.67 |
Lower Bollinger Band | 213.04 |
Percent B (%b) | 0.56 |
BandWidth | 16.23 |
MACD Line | 5.21 |
MACD Signal Line | 5.23 |
MACD Histogram | -0.0159 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 245.15 | ||||
Resistance 3 (R3) | 244.92 | 240.96 | 243.29 | ||
Resistance 2 (R2) | 240.96 | 238.11 | 241.08 | 242.67 | |
Resistance 1 (R1) | 237.47 | 236.35 | 235.49 | 237.70 | 242.05 |
Pivot Point | 233.51 | 233.51 | 232.52 | 233.62 | 233.51 |
Support 1 (S1) | 230.01 | 230.66 | 228.03 | 230.24 | 225.89 |
Support 2 (S2) | 226.05 | 228.90 | 226.17 | 225.27 | |
Support 3 (S3) | 222.56 | 226.05 | 224.65 | ||
Support 4 (S4) | 222.79 |